中国新冠病毒疫苗附条件上市

我国5个疫苗进入Ⅲ期临床试验
发布会上，国家药品监督管理局副局长陈时飞介绍，国药集团中国生物新冠灭活疫苗已获得国家药监局批准附条件上市。已有数据显示，保护率为79.34%，实现安全性、有效性、可及性、可负担性的统一，达到世界卫生组织及国家药监局相关标准要求。后续，疫苗免疫的持久性和保护效果还需持续观察。

此外，科学技术部副部长徐南平表示，到目前为止，我国5条技术路线14个疫苗进入临床试验，其中3条技术路线5个疫苗进入Ⅲ期临床试验。

北京、湖北承担新冠疫苗批签发工作
发布会上，陈时飞表示，目前已授予北京市和湖北省药品监管和检验机构承担新冠疫苗的批签发工作。批签发机构将按照有关法规及管理办法，对每一批疫苗实行严格审核和检验，确保每一支疫苗是合格的。

新冠变异病毒对疫苗的使用效果是否有影响？

发布会上，徐南平表示，科研攻关组召开多次会议，专家认为目前没有证据证明新冠变异病毒会对疫苗的使用效果造成实质性影响，但需要高度关注。

批准上市的疫苗价格如何？

国家卫生健康委员会副主任曾益新表示，新冠病毒疫苗的基本属性是公共产品，价格根据使用规模的大小会有所变化，但是一个大前提肯定是为全民免费提供。

我国重点人群接种疫苗超300万剂次，安全性良好
发布会上，曾益新介绍新冠疫苗重点人群接种工作情况。他表示，我国疫苗研发始终属于全球第一方阵：
自12月15日正式启动重点人群接种工作以来，目前累计接种超过300万剂次。

接种结果充分证明我国疫苗安全性良好，发生了一定比例的不良反应，总的发生率与常规接种的灭活疫苗接近。

主要表现是局部疼痛、硬结，轻度发热比例大概不到0.1%，过敏等比较严重的情况为百万分之二，这些情况经过及时处理都得到很好的治疗。

接下来将全面推进老年人和有基础疾病的人群进行接种，后续再开展其他普通人群的接种，未来符合条件的群众都将实现“应接尽接”。

疫苗研发绝不会为了争第一而“抢跑”
发布会上，新冠疫苗研发专班工作组组长郑忠伟表示，疫苗研发过程是在和病毒赛跑，但我们充分尊重疫苗研发的科学规律和科学原则。
我国是最早开展临床试验，也是最早开展Ⅲ期临床试验。但是由于我国疫情控制得好，我们在境外开展临床试验，在临床试验过程中严格遵守相关规则，绝不会为了争第一而“抢跑”。

Five vaccines in China enter phase III clinical trials

At the press conference, Chen Shifei, deputy director of the State Drug Administration, said that Sinopharm's China Bio new crown inactivated vaccine had been approved by the State Drug Administration for conditional marketing. The existing data show that the protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, meeting the relevant standards of who and SFDA. In the future, the persistence and protective effect of the vaccine should be observed continuously.

In addition, Xu Nanping, Vice Minister of the Ministry of science and technology, said that so far, 14 vaccines from five technical routes have entered clinical trials in China, of which five vaccines from three technical routes have entered phase III clinical trials.

Grant of new vaccines in Beijing and Hubei
At the press conference, Chen Shifei said that the drug regulatory and inspection institutions in Beijing and Hubei Province have been awarded the task of issuing the new crown vaccine in batches. In accordance with relevant regulations and administrative measures, the batch issuing agency will strictly audit and inspect each batch of vaccines to ensure that each vaccine is qualified.

Does the new coronavirus mutation affect the efficacy of the vaccine?

At the press conference, Xu Nanping said that the scientific research team has held many meetings, and experts believe that there is no evidence that the new coronavirus mutation will have a substantial impact on the use of the vaccine, but it needs high attention.

What is the price of the approved vaccine?

Zeng Yixin, deputy director of the National Health Commission, said that the basic attribute of the new coronavirus vaccine is public goods, and the price will change according to the scale of use, but one major premise is definitely to provide free for all.

Over 3 million doses of the vaccine have been given to key population in China, with good safety
At the press conference, Zeng Yixin introduced the vaccination work of key groups of Xinguan vaccine. He said that China's vaccine research and development has always been the first in the world
Since the official launch of vaccination work for key population on December 15, the cumulative number of inoculations has exceeded 3 million.

The results of vaccination fully proved that the safety of vaccine in China was good, a certain proportion of adverse reactions occurred, and the total incidence was close to that of conventional inactivated vaccine.

The main performance is local pain, induration, mild fever rate is less than 0.1%, allergy and other serious situation is two parts per million, these situations after timely treatment are very good treatment.

Next, we will comprehensively promote the vaccination of the elderly and people with basic diseases, and then carry out the vaccination of other ordinary people. In the future, all the eligible people will be able to "receive as much as possible.".

Sinopharm China Biological New Crown inactivated vaccine has been approved by the State Food and Drug Administration for conditional listing

Vaccine research and development will never "rush" for the first place

At the press conference, Zheng Zhongwei, head of the working group of new crown vaccine research and development, said that the vaccine research and development process is a race against the virus, but we fully respect the scientific laws and principles of vaccine research and development.
China is the first to carry out clinical trials, and also the first to carry out phase III clinical trials. However, due to the good control of the epidemic situation in our country, we carry out clinical trials abroad, strictly abide by the relevant rules in the process of clinical trials, and will never "rush" for the first place.

　　近年来，随着人们对手机功能的需求越来越多，为了满足用户的多方面需求，手机屏幕也发展的越来越大，但因为目前手机屏幕主要是用玻璃材质，在日常使用中经常会出现划痕，用户一般都会选择贴膜来保护屏幕，而华为近日公布的专利技术可使手机不在需要贴膜的保护。

近日，国家专利局的公告显示华为在 2019 年 6 月 20 日申请了一项新型的发明专利，专利名为“一种玻璃划痕的修复方法及修复设备”，该技术可以采用一种修复设备来检测并修复手机屏幕玻璃的划痕。

屏幕修复设备可自动检测划痕并修复

　　根据专利介绍，，该技术将采用修复设备检测玻璃表面是否存在划痕，在受损的玻璃表面上的划痕滴加修复液并在其表面贴敷透明薄膜。随后，修复设备对修复液进行固化，在划痕上形成树脂修复层，最后修复设备再剥离透明薄膜。

　　在这项技术中，修复设备可以自动将修复液覆盖在划痕上，并可以使修复液能充分浸润划痕表面，该方法可适用于对电子设备的玻璃表面的划痕进行修复，对于玻璃表面上的小尺寸的划痕，也可以有效、无损的实现对划痕进行修复。

Turkish health minister Kejia said on the evening of the 24th that Turkey has confirmed that the new inactivated vaccine developed by China's Beijing Kexing zhongweisheng Technology Co., Ltd. is effective and safe for the Turkish people.

Kejia said at a news conference that night that the preliminary analysis of the data of volunteers who voluntarily vaccinated with kexingxinguan vaccine in Turkey showed that the effectiveness of kexingxinguan vaccine reached 91.25%, and no serious side effects were found during the clinical trial. China has approved the export of vaccines to Turkey. If all goes well, the first 3 million doses of vaccines from China will arrive in Turkey in the near future.

Kejia also said that in the first stage, 9 million people will be vaccinated, mainly for high-risk groups such as medical staff.

Data released on the website of Turkey's Ministry of health on the 25th showed that 201104 people in Turkey were tested for new coronavirus on the same day, with 17543 newly diagnosed cases, of which 3199 were symptomatic infections, with a total of 2118255 confirmed cases; 256 new deaths, with a total of 19371 deaths; 1970803 cured cases.

In addition to Turkey, the Brazilian health department also disclosed the effectiveness of China's Kexing vaccine, which met the international standards. Kovas, director of Brazil's Butantan Research Institute, said that the Chinese vaccine is the safest currently tested in Brazil, and it has given the Brazilian people light.

December 28 news: on the morning of May 23, 2019, China launched the remote sensing 33 satellite with the long march 4C carrier rocket at the Taiyuan Satellite Launch Center. The third stage of the rocket and the debris of the satellite fell, so the satellite launch was declared a failure.

According to CCTV news, at 23:44 on December 27, 2020, China successfully launched the remote sensing 33 satellite into the predetermined orbit with the long march 4C carrier rocket at Jiuquan Satellite Launch Center, and the launch was a complete success. At this point, China's space industry has a perfect ending in 2020.

It is worth mentioning that the mission also launched a micro nano technology test satellite.

China's successful launch of rs-33 satellite brings China's space industry to a perfect end in 2020.

Remote sensing satellite 33 and micro nano technology test satellite are mainly used in scientific experiments, land and resources census, agricultural product yield estimation, disaster prevention and mitigation and other fields. This mission is the 357th flight of long march series launch vehicles.